☆ 4.7 Editorial Material

Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination

LANCET INFECTIOUS DISEASES (2023)

Related references

Note: Only part of the references are listed.
Article Public, Environmental & Occupational Health

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022

Kristie E.N. Clarke et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection
Article Medicine, General & Internal

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections

Heba N. Altarawneh et al.

Summary: An analysis of data from Qatar showed that previous infection, vaccination, and hybrid immunity all demonstrated effectiveness in protecting against symptomatic Covid-19 caused by the BA.1 and BA.2 sublineages of the Omicron variant.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Medicine, General & Internal

Covid-19 Vaccine Protection among Children and Adolescents in Qatar

Hiam Chemaitelly et al.

Summary: A study in Qatar found that the BNT162b2 vaccine provided modest and rapidly waning protection against Covid-19 in children aged 5 to 11, while it gave stronger and more durable protection in adolescents aged 12 to 17, possibly due to the higher antigen dose.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Medicine, General & Internal

Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada

Sara Carazo et al.

Summary: This study found that individuals who had prior heterologous SARS-CoV-2 infection and received 2 or 3 doses of mRNA vaccine provided the greatest protection against Omicron-associated hospitalization. A third mRNA vaccine dose may offer limited additional protection in twice-vaccinated individuals with prior SARS-CoV-2 infection.

JAMA NETWORK OPEN (2022)

Add to Collection
Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.